Fig. 2: Kaplan-Meier curves for cumulative incidence of infections with teclistamab.
From: Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
A Cumulative incidence of all-grade infections. B Cumulative incidence of grade 3 or higher infections.
